# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the T...
The highlights of presentation are as follows: The primary endpoints were safety and tolerability of MN-166 and TMZ combinatio...
Abstract Number: 2106 Title: Phase 1b/2a study evaluating the combination of MN-166 (ibudilast) and temozolomide in patients ...